News & Updates
Filter by Specialty:
Belzutifan a ray of hope for VHL-associated renal cancer?
In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.
Belzutifan a ray of hope for VHL-associated renal cancer?
07 Jan 2022
Biologic-naïve IBD patients on anti-TNFα warrant treatment intensification
Treatment intensification is needed in around one-third of biologic-naïve patients with inflammatory bowel disease (IBD) who had received initial antitumour necrosis factor α (anti-TNFα) medication, a recent study has found.
Biologic-naïve IBD patients on anti-TNFα warrant treatment intensification
07 Jan 2022
First-line cabozantinib-atezolizumab boosts PFS in advanced HCC
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.
First-line cabozantinib-atezolizumab boosts PFS in advanced HCC
06 Jan 2022
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
Four cycles of neoadjuvant chemotherapy (NACT) results in better pathological response and survival than three NACT cycles in patients with muscle invasive bladder cancer, reveals a recent study.
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
06 Jan 2022
Chronic constipation patients unhappy with conventional treatments: survey
Conventional treatment options for chronic constipation (CC) are not effective enough to improve symptoms or satisfaction among patients, results of an internet survey in Japan have shown.
